Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price fell 0.2% on Thursday . The stock traded as low as $24.95 and last traded at $25.17. 13,432,213 shares were traded during trading, a decline of 63% from the average session volume of 36,662,661 shares. The stock had previously closed at $25.21.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.
Check Out Our Latest Report on PFE
Pfizer Stock Performance
The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm's fifty day moving average price is $26.06 and its 200 day moving average price is $26.92. The firm has a market capitalization of $142.93 billion, a PE ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.
Hedge Funds Weigh In On Pfizer
A number of institutional investors have recently modified their holdings of the company. Nordea Investment Management AB lifted its position in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI lifted its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares during the period. NFJ Investment Group LLC grew its holdings in shares of Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after purchasing an additional 43,719 shares in the last quarter. Copley Financial Group Inc. bought a new stake in shares of Pfizer in the 3rd quarter worth about $577,000. Finally, Zacks Investment Management lifted its holdings in Pfizer by 10.9% during the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock valued at $69,142,000 after purchasing an additional 235,243 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
